OPTIC = Ponatinib in resistant chronic phase CML

Study title

OPTIC = Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses [Africa, Asia, Australia, Europe, North- and South America]

Scientific title

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses (EudraCT 2014-001617-12, NCT02467270)

Indication and most important inclusion criteria

This study includes patients 18 years and older with chronic myeloid leukemia (CML) in chronic phase (CP) who are resistant to at least two tyrosine kinase inhibitors (TKI). Eligible patients should have an Eastern Co-Operative Group (ECOG) performance status of 0, 1 or 2 as well as adequate kidney and liver function.

Short description of intervention

This is a study to compare and characterize the safety and efficacy of ponatinib over a range of 3 starting doses (45 mg, 30 mg and 15 mg daily) in patients with chronic phase CML who are resistant to at least two tyrosine kinase inhibitors, as measured by major cytogenetic response by 12 month.

Type of study

Therapy optimization trials

Current status


Study sponsor

Ariad Pharmaceuticals

Scientific lead / contact

Sergio Santillana MD, Ariad Pharmaceuticals

Principal investigator

See site contact information

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study centers / principal investigators


New South Wales
St. Leonards, New South Wales, 2065
Royal North Shore Hospital (Site 941)
Contact: Vicki Katsioulas
Principal Investigator: Christopher K Arthur, MD

Adelaide, 5000
Royal Adelaide Hospital, Haematology Clinical Trials (Site 951)
Principal Investigator: Professor Timothy Peter Hughes


Gent, 9000
UZ Gent (Site 756)
Principal Investigator: Prof. Dr. Lucien Noens

Leuven, 3000
UZ Leuven Campus Gasthuisberg (Site 700)
Principal Investigator: Prof. Dr. Gregor Verhoef


Toronto, Ontario, M5G2M9
Princess Margaret Cancer Centre (Site 083)
Principal Investigator: Jeffrey Howard Lipton

Montreal, Quebec, H3T IE2 Jewish General Hospital (Site 129)
Contact: Marie Pascale Guay
Principal Investigator: Sarit Assouline, MD

Regina, Saskatchewan, S4T 1A5
Pasqua Hospital (Site 227)
Principal Investigator: Haji Chalchal, MD


Vina del Mar, Quinta Regin, 254-0364
Centro de Investigaciones Clínicas Viña del Mar (Site 828)
Contact: Gina Castagneto
Principal Investigator: Christine Rojas Hopkins, MD


Hong Kong
Queen Mary Hospital (Site 973)
Principal Investigator: Prof. Kwong Yok-Lam

Czech Republic
Olomouc, 77520
Fakultni nemocnice Olomoue (Site 515)
Principal Investigator: prof. Karel Indrak, MD, PhD

Praha 2, 128 20
The Institute of Hematology and Blood Transfusion (UHKT) (Site 516)
Contact: Jana Vedrova
Principal Investigator: Hana Klamova


Aarhus C, 8000
Haematologisk Afdeling, Arahus Universitehospital (Site 683)
Principal Investigator: Prof. Jesper Stentoft, M.D.


Jyvaskyla, 70029 Kuopio
Central Finland Central Hospital, Hematological Unit (Site 684)
Principal Investigator: Marita Nurmi


Angers Cedex 9, 44093 CHU Angers, Service Maladies du Sang (Site 685)
Principal Investigator: Dr. Martine Gardembas

Bordeaux, 33076
Institut Bergonie, Institut Bergonie (Site 772)
Principal Investigator: Dr. Gabriel Etienne

Lille, Nord, 59037 CEDEX Hopital Claude Huriez CHRU (Site 952)
Contact: Sylvie Brice
Principal Investigator: Valerie Coiteux, MD

Nantes Cedex, 44093
CHU Hotel-Dieu, Service d'Hematologie Clinique (Site 521)
Principal Investigator: Dr. Viviane Dubruille

Nice Cedex 3, 06202
Hopital Archet 1 (Site 509)
Contact: Marie-Christine Rigualt
Principal Investigator: Laurence Legros

Poitiers, B.p. 577, 86021
CHRU de Poitiers, Department of Oncology-Hematology and Cell Therapy (Site 954)
Principal Investigator: Prof. Francois Guilhot

Vandoeuvre-les-Nancy Cedex, 54511
University Teaching Hospital - CHU Brabois (Site 953)
Principal Investigator: Dr. Agnes-Paule Guerci-Bresler


Verona, 37134
Ospedale Borgo Roma - Verona (Site 687)
Contact: Giorgia Barbiero
Principal Investigator: Massimiliano Bonifacio, MD


Okayama, 700-8558
Okayama University Hospital (Site 418)
Contact: Toshimitsu Konuma
Principal Investigator: Yoshinobu Maeda, MD

Osaka, 545-0051
Osaka City University Hospital (Site 413)
Contact: Miyuki Amakawa
Principal Investigator: Hirohisa Nakamae

Korea, Republic of

Seoul, Korea, Republic of, 137-701
The Catholic University of Korea Seoul St. Mary's Hospital (Site 938)
Principal Investigator: Dong-Wook Kim, M.D., PhD


Bergen, 5021
Bergens Universitetssjukhus (Site 690)
Contact: Ingeborg Tennebekk Nessa
Principal Investigator: Bjorn T Gjertsen, MD, PhD


Outram Road, Singapore, 169608 Singapore General Hospital (Site 939)
Principal Investigator: Dr. Charles Chuah Thuan Heng


Barcelona, Cataluna, 08036
Hospital Clinic, Service de Hematologia (Site 963)
Principal Investigator: Francisco Cervantes

Las Palmas de Gran Canaria, Islas Canarias, 35010
Hospital Universitario de Gran Canaria Dr Negrin (Site 692)
Contact: Mireya A Lopez
Principal Investigator: Maria Teresa Gomez Casares, MD

Madrid, 28006
Hospital Universitario de la Princesa, Hematology Servicem 2a Planta (Site 555)
Principal Investigator: Juan Luis Steegmann Olmedillas

Madrid, 28034
Hospital Universitario Ramon y Cajal (Site 538)
Principal Investigator: Valentin Garcia Gutierrez
Hospital Clinico Universitario de Valencia (Site 964)

Malaga, Andalucia, 29010
Hospital Regional Universitario Carlos Haya (Site 698)
Principal Investigator: Antonio Jimenez Velasco

Valencia, Spain, 46010
Hospital Universitari i Politecnic La Fe (Site 666)
Principal Investigator: Juan Carlos Hernandez Boluda

Valencia, Spain, 46026
Contact: Maria Tordera
Principal Investigator: Jaime Sanz Caballer


Uppsala, SE-751 85
University Hospital Uppsala (Site 945)
Contact: Aime Mukenyuzi
Principal Investigator: Ulla Olsson-Stromberg, M.D., Ph.D.


Taipei, 100
National Taiwan University Hospital (Site 979)
Principal Investigator: Jih-Luh Tang, M.D., PhD.

United Kingdom

Glasgow, G12 0YN
NHS Greater Glasgow & Clyde, The Beatson West of Scotland Cancer Centre (Site 797)
Principal Investigator: Professor Tessa Holyoake

Liverpool, L7 8XP
The Royal Liverpool University Hospital (Site 969)
Principal Investigator: Professor Richard Clark

London, SE5 9RS
King's College Hospital NHS Foundation Trust (Site 693)
Principal Investigator: Dr. Hugues de Lavallade

London, W120NN
Hammersmith Hospital (Site 967)
Contact: Regina Storch
Principal Investigator: Jane F Apperley, MD

Newcastle Upon Tyne, NE7 7DN
The New Castle Upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital (Site 970)
Contact: Mai Kay Jones
Principal Investigator: Wendy Osborne

Nottingham, NG5 1PB
The Centre for Clinical Haematology, Notthingham University Hospitals NHS Trust (Site 968)
ontact: Maria Scott
Principal Investigator: Jennifer Byrne

United States

City of Hope
Duarte, California, 91010 (Site 009)
Principal Investigator: David S. Snyder, MD

Atlanta, Georgia, 30322
Emory University Hospital (Site 058)
Principal Investigator: Vamsi Kota, MD

Indianapolis, Indiana, 46237
Indiana Blood and Marrow Transplantation Clinic (Site 138)
Principal Investigator: Luke Akard, MD

Iowa City, Iowa, 52242
University of Iowa Hospitals and Clinics (Site 050)
Principal Investigator: Usha Perepu, MD

Baltimore, Maryland, 21201
University of Maryland, Greenbaum Cancer Center (Site 040)
Principal Investigator: Maria Baer, MD

Ann Arbor, Michigan, 48109
University of Michigan Health System (Site 011)
Principal Investigator: Moshe Talpaz, MD

Detroit, Michigan, 48201
Karmanos Cancer Institute (Site 034)
Principal Investigator: Charles Schiffer, MD

Omaha, Nebraska, 68198-7680
University of Nebraska Medical Center (Site 235)
Principal Investigator: Lori Maness-Harris, MD

New Jersey
Hackensack, New Jersey, 07601
Hackensack University Medical Center (Site 128)
Principal Investigator: James McCloskey II

New York
New York, New York, 10065
Memorial Sloan Kettering Cancer Center (Site 078)
Contact: Gerald O'Neill
Principal Investigator: Michael Mauro, MD

New York, New York, 10065
Weill Medical College of Cornell University and New York Presbyterian Hospital (Site 006)
Contact: Rachael Alettie
Principal Investigator: Ellen Ritchie, MD

North Carolina
Durham, North Carolina, 27710
Duke University Medical Center (Site 003)
Contact: Cheryl M Maxey
Principal Investigator: Joseph Moore, MD

Cleveland, Ohio, 44195
Cleveland Clinic Foundation (Site 004)
Principal Investigator: Dr. Sudipto Mukherjee

Portland, Oregon, 97239
Oregon Health & Science University (Site 048)
Contact: Jeanne Liming
Principal Investigator: Michael Heinrich

Philadelphia, Pennsylvania, 19104
Hospital of the University of Pennsylvania (Site 013)
Principal Investigator: Selena Luger, MD

Houston, Texas, 77030
MD Anderson Cancer Center (Site 005)
Principal Investigator: Jorge E. Cortes, MD

Salt Lake City, Utah, 84112
Huntsman Cancer Institute (Site 043)
Principal Investigator: Michael Deiningeri, MD